Retatrutide vs Carnosine
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
RetatrutideAnti-Aging & LongevityRecovery & Repair
Carnosine- Summary
- Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
- Carnosine is an endogenous dipeptide (beta-alanine + histidine) found in high concentrations in muscle and brain. It is a potent anti-aging molecule with broad spectrum antioxidant, anti-glycation, anti-carbonylation, and metal chelating properties, making it one of the most protective naturally occurring dipeptides.
- Half-Life
- ~10–12 days
- ~1.5 minutes (rapidly hydrolyzed to beta-alanine and histidine by carnosinase in blood; tissue levels maintained via constant synthesis)
- Admin Route
- SubQ
- Oral, Topical
- Research
- —
- —
- Typical Dose
- 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
- 1,000–2,000 mg
- Frequency
- Once weekly
- Once to twice daily with meals
- Key Benefits
- ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
- Superior to both semaglutide and tirzepatide in early trial comparisons
- Triple receptor mechanism addresses multiple obesity pathways
- Significant reduction in liver fat (MASH/NAFLD indication being studied)
- Improved cardiovascular and metabolic markers
- Once-weekly dosing
- Potential for greatest weight loss of any currently investigated compound
- Potent anti-glycation (prevents protein cross-linking/aging)
- Broad-spectrum antioxidant in muscle and brain
- Extends cell lifespan and protects telomeres
- Improves muscle performance and delays fatigue (pH buffering)
- Neuroprotective against Alzheimer's amyloid-beta
- Wound healing acceleration
- Anti-cataract properties (eye health)
- Improves diabetes complications via AGE prevention
- Chelates excess copper and zinc
- Side Effects
- Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
- Diarrhea
- Constipation
- Heart rate increase (from glucagon receptor agonism)
- +2 more
- Very well tolerated
- Rare: mild GI discomfort at high doses
- No significant adverse effects in human studies
- Stacks With
- —
- —